Publications 2016

Publications auxquelles l’Aretasc a participé en 2016 :

DPYD genotyping to predict adverse events following treatment with fluorouracil-
based adjuvant chemotherapy in patients with stage III colon cancer

A secondary analysis of the PETACC 8 randomized clinical trial.
Boige V, Vincent M, Alexandre P
JAMA Oncol 2016 Jan 21. doi :10,1001

Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab

A post hoc analysis of the PETACC-8 trial.
Taieb J, ZaananA, Le Malicot K. JAMA Oncol 2016 jan 15/14.1-11

Primary analysis of the Eortc 1004/BIG 3-04 Mindact study

A prospective, randomized study evaluating the clinical utility of the 70-gene signature (mammaPrint) combined with common clinical pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes.
M.Piccart, E.Rutgers S.Delage ; AACR, April 28, 2016

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclosphosphamide in node-positive breast cancer.

CRIG-005 randomized trial. Mcacket JR, Pienkowski T, Crown J
AnnOncol (2016 ) V 27(6) :1041-1047 doi : 10.1093/annonc/mdw 098.

Concomitant ou séquentiel pour le trastuzumab adjuvant

Etude combinée de PHARE et SIGNAL : Esmo 2016 PivotX et al ; abstr 1440

Enquête PONDx en France

Enquête d’utilisation du test Oncotype DX en
practique clinique courante. Courtit E, Bourgeois H, Laharie H, Vannetzel JM, Bonichon-Lamichhane N

Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16)

A randomised, multicentre, open-label phase 3 trial.
The Lancet Oncology Volume 17, No. 6, p747–756, June 2016 : Carrie C, Hasbini A,
Delaroche G